solute carrier family 2 member 5Genealiases: GLUT-5 · GLUT5
Q-omics provides the consensus-scored SLC2A5 profile across patient tissues and cancer cell-line models. SLC2A5 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, SLC2A5 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, SLC2A5 RNA expression shows 22,701 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight SKCM, KIRC, and GBM as cancer lineages where SLC2A5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC2A5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC2A5 survival associations across molecular data types. SLC2A5 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC2A5 RNA expression–survival associations across cancer types. High SLC2A5 expression shows unfavorable associations in LAML, KICH, LIHC and LGG, but favorable associations in SKCM and KIRC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for SLC2A5 RNA expression.
This table summarizes SLC2A5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SLC2A5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC2A5 shows lower tumor expression in COAD and KICH and higher tumor expression in KIRC, LUAD, LUSC and LIHC. The KIRC box plot shows higher SLC2A5 RNA expression in tumor versus normal tissue (log2 FC = +3.219, t-test p < 0.001).
This table shows molecular features associated with SLC2A5 in patient tissues and cancer cell lines. In patient samples, SLC2A5 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC2A5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Lymphoma.
